JP2018501258A5 - - Google Patents

Download PDF

Info

Publication number
JP2018501258A5
JP2018501258A5 JP2017533485A JP2017533485A JP2018501258A5 JP 2018501258 A5 JP2018501258 A5 JP 2018501258A5 JP 2017533485 A JP2017533485 A JP 2017533485A JP 2017533485 A JP2017533485 A JP 2017533485A JP 2018501258 A5 JP2018501258 A5 JP 2018501258A5
Authority
JP
Japan
Prior art keywords
influenza
polypeptide
recombinant
immunogenic composition
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017533485A
Other languages
English (en)
Japanese (ja)
Other versions
JP6764408B2 (ja
JP2018501258A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/066882 external-priority patent/WO2016100922A1/en
Publication of JP2018501258A publication Critical patent/JP2018501258A/ja
Publication of JP2018501258A5 publication Critical patent/JP2018501258A5/ja
Application granted granted Critical
Publication of JP6764408B2 publication Critical patent/JP6764408B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017533485A 2014-12-19 2015-12-18 Ｈ１ｎ１インフルエンザに対するコンピュータ最適化広反応性抗原の相乗的併用投与 Expired - Fee Related JP6764408B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462094772P 2014-12-19 2014-12-19
US62/094,772 2014-12-19
PCT/US2015/066882 WO2016100922A1 (en) 2014-12-19 2015-12-18 Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020131336A Division JP2020186252A (ja) 2014-12-19 2020-08-03 Ｈ１ｎ１インフルエンザに対するコンピュータ最適化広反応性抗原の相乗的併用投与

Publications (3)

Publication Number Publication Date
JP2018501258A JP2018501258A (ja) 2018-01-18
JP2018501258A5 true JP2018501258A5 (https=) 2019-01-31
JP6764408B2 JP6764408B2 (ja) 2020-09-30

Family

ID=56127736

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017533485A Expired - Fee Related JP6764408B2 (ja) 2014-12-19 2015-12-18 Ｈ１ｎ１インフルエンザに対するコンピュータ最適化広反応性抗原の相乗的併用投与
JP2020131336A Pending JP2020186252A (ja) 2014-12-19 2020-08-03 Ｈ１ｎ１インフルエンザに対するコンピュータ最適化広反応性抗原の相乗的併用投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020131336A Pending JP2020186252A (ja) 2014-12-19 2020-08-03 Ｈ１ｎ１インフルエンザに対するコンピュータ最適化広反応性抗原の相乗的併用投与

Country Status (7)

Country Link
US (2) US10220086B2 (https=)
EP (1) EP3233116A4 (https=)
JP (2) JP6764408B2 (https=)
CN (1) CN107530417A (https=)
AU (1) AU2015364253B2 (https=)
CA (1) CA2970158A1 (https=)
WO (1) WO2016100922A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2970158A1 (en) * 2014-12-19 2016-06-23 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
WO2019108319A1 (en) * 2017-12-01 2019-06-06 Kemin Industries, Inc. Compositions containing euglena gracilis for viral protection and related methods
US12521430B2 (en) 2018-03-28 2026-01-13 Sanofi Pasteur Inc. Methods of generating broadly protective vaccine compositions comprising neuraminidase
WO2020092207A1 (en) * 2018-10-28 2020-05-07 University Of Georgia Research Foundation Broadly reactive immunogens of influenza virus, compositions, and methods of use thereof
JP2024522193A (ja) * 2021-06-10 2024-06-11 ユニバーシティ オブ ジョージア リサーチ ファウンデイション， インコーポレイテッド 免疫原としての広範囲反応性ウイルス抗原、その組成物及び使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100221284A1 (en) * 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
USH2283H1 (en) * 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
CA2868330A1 (en) * 2012-03-30 2013-10-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses
SG11201503989PA (en) * 2012-11-27 2015-06-29 Univ Pittsburgh Computationally optimized broadly reactive antigens for h1n1 influenza
KR20150138184A (ko) * 2013-02-11 2015-12-09 노바백스, 인코포레이티드 호흡기 세포 융합 바이러스 및 인플루엔자를 위한 조합 백신
CA2970158A1 (en) * 2014-12-19 2016-06-23 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza
US10927151B2 (en) 2015-06-09 2021-02-23 Sanofi Pasteur Inc. Methods of optimizing nucleotide sequences encoding engineered influenza proteins
US20200237898A1 (en) * 2015-09-21 2020-07-30 Oregon Health & Science University Vaccines intelligently produced by epitope recombination (viper) for influenza

Similar Documents

Publication Publication Date Title
JP2018501258A5 (https=)
JP2015186478A5 (https=)
JP2016506416A5 (https=)
JP2009511084A5 (https=)
WO2019246363A8 (en) Mosaic influenza virus hemagglutinin polypeptides and uses thereof
JP2016199557A5 (https=)
RU2015132962A (ru) Иммуногенные композиции на основе вируса гриппа и их применение
JP2016520530A5 (https=)
JP2018504412A5 (https=)
JP2015214545A5 (https=)
WO2009026397A3 (en) Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
JP2014502156A5 (https=)
ES2673556T3 (es) Vacunas para el VHS-2
IL276210B2 (en) Mers-cov vaccine
JP2010500399A5 (https=)
JP2019530462A5 (https=)
JP2015522540A5 (https=)
JP2016539946A5 (https=)
JP2016534034A5 (https=)
JP2008530245A5 (https=)
PE20142330A1 (es) Vacuna de peptido ch3 de ige
JP2013518052A5 (https=)
JP2010508030A5 (https=)
CY1125681T1 (el) Εμβολια κατα του ιου της γριπης και χρησεις αυτων
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.